Oxycodone User Registry (OUR)

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to describe clinical and demographic characteristics of patients receiving prescription medications containing oxycodone immediate release (OXYRX), to characterize patient and prescriber perceptions of the effectiveness outcomes and tolerability of OXYRX treatment, to describe prescriber decision-making about pain management with a Schedule II opioid and to explore how prescribers identify suspected abuse of pain medications.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
• Treatments: Oxycodone

Criteria

Inclusion Criteria:

• Pain requiring treatment with a Schedule II immediate release opioid within 3 days following the baseline visit

• and pain that warrants treatment with a prescription for OXYRX PRN (alone or in combination) for at least 5 days after the baseline visit

Exclusion Criteria:

• Use of any Schedule II opioid within 30 days prior to informed consent

• planned use of other opioids (Schedule II-V) while using OXYRX

• malignancy other than superficial skin cancers (ie, basal cell, squamous cell) within the past year